Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVDL Avadel Pharmaceuticals	$13.40 +4.8%	$10.12	$6.38 ▼ $16.84	$1.30B	1.47	1.35 million shs	1.38 million shs
PCVX Vaxcyte	$30.00 +1.1%	$34.32	$27.66 ▼ $121.06	$3.89B	1.21	1.79 million shs	2.10 million shs
PTCT PTC Therapeutics	$45.27 +4.5%	$49.33	$30.41 ▼ $58.38	$3.60B	0.54	1.06 million shs	1.16 million shs
ZLAB Zai Lab	$34.31 -1.0%	$36.70	$16.01 ▼ $44.34	$3.81B	1.03	995,749 shs	394,193 shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVDL Avadel Pharmaceuticals	+0.31%	+13.59%	+33.09%	+41.64%	-17.54%
PCVX Vaxcyte	-0.77%	-12.01%	-17.42%	-1.26%	-61.91%
PTCT PTC Therapeutics	-4.58%	-17.13%	-10.81%	-6.66%	+38.38%
ZLAB Zai Lab	-0.86%	-8.91%	+5.90%	+21.10%	+113.16%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AVDL Avadel Pharmaceuticals	2.6331 of 5 stars	3.5	2.0	0.0	3.1	1.7	0.6
PCVX Vaxcyte	2.0268 of 5 stars	3.5	2.0	0.0	2.3	1.7	0.0
PTCT PTC Therapeutics	4.5482 of 5 stars	4.3	2.0	4.4	3.2	0.8	1.3
ZLAB Zai Lab	2.3652 of 5 stars	3.4	2.0	0.0	2.5	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AVDL Avadel Pharmaceuticals	3.00	Buy	$18.67	39.30% Upside
PCVX Vaxcyte	3.09	Buy	$136.50	355.00% Upside
PTCT PTC Therapeutics	2.63	Moderate Buy	$70.15	54.97% Upside
ZLAB Zai Lab	2.83	Moderate Buy	$57.22	66.77% Upside

Current Analyst Ratings Breakdown

Latest AVDL, PCVX, PTCT, and ZLAB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/11/2025	ZLAB Zai Lab	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$66.00 ➝ $69.00
8/8/2025	PTCT PTC Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$70.00
8/8/2025	PTCT PTC Therapeutics	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
8/8/2025	PTCT PTC Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$60.00 ➝ $63.00
8/8/2025	AVDL Avadel Pharmaceuticals	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
8/8/2025	AVDL Avadel Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$22.00 ➝ $24.00
8/8/2025	PTCT PTC Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$78.00 ➝ $79.00
8/7/2025	PCVX Vaxcyte	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
7/29/2025	PTCT PTC Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$80.00 ➝ $86.00
7/29/2025	PTCT PTC Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$42.00 ➝ $46.00
7/29/2025	PTCT PTC Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$68.00 ➝ $84.00

(Data available from 8/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AVDL Avadel Pharmaceuticals	$169.12M	7.67	N/A	N/A	$0.77 per share	17.40
PCVX Vaxcyte	N/A	N/A	N/A	N/A	$26.52 per share	N/A
PTCT PTC Therapeutics	$806.78M	4.46	N/A	N/A	($14.24) per share	-3.18
ZLAB Zai Lab	$427.80M	8.91	N/A	N/A	$7.68 per share	4.47

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AVDL Avadel Pharmaceuticals	-$48.83M	-$0.03	N/A	223.33	N/A	-1.32%	-3.73%	-1.73%	N/A
PCVX Vaxcyte	-$463.93M	-$4.11	N/A	N/A	N/A	N/A	-16.85%	-15.92%	N/A
PTCT PTC Therapeutics	-$363.30M	$6.97	6.49	N/A	N/A	35.65%	-86.77%	32.71%	N/A
ZLAB Zai Lab	-$257.10M	-$2.04	N/A	N/A	N/A	-49.68%	-27.32%	-18.85%	N/A

Latest AVDL, PCVX, PTCT, and ZLAB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	AVDL Avadel Pharmaceuticals	$0.02	$0.10	+$0.08	$0.10	$60.28 million	$68.13 million
8/7/2025	Q2 2025	PTCT PTC Therapeutics	-$1.07	-$0.83	+$0.24	-$0.83	$173.01 million	$178.88 million
8/7/2025	Q2 2025	ZLAB Zai Lab	-$0.37	-$0.37	N/A	-$0.37	$125.66 million	$109.98 million
8/6/2025	Q2 2025	PCVX Vaxcyte	-$1.12	-$1.22	-$0.10	-$1.22	N/A	N/A
5/14/2025	Q1 2025	PCVX Vaxcyte	-$1.02	-$1.04	-$0.02	-$1.04	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AVDL Avadel Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
PCVX Vaxcyte	N/A	N/A	N/A	N/A	N/A
PTCT PTC Therapeutics	N/A	N/A	N/A	N/A	N/A
ZLAB Zai Lab	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AVDL Avadel Pharmaceuticals	N/A	2.79	2.38
PCVX Vaxcyte	N/A	11.11	11.11
PTCT PTC Therapeutics	N/A	3.89	3.85
ZLAB Zai Lab	N/A	3.12	2.93

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AVDL Avadel Pharmaceuticals	69.19%
PCVX Vaxcyte	96.78%
PTCT PTC Therapeutics	N/A
ZLAB Zai Lab	41.65%

Insider Ownership

Company	Insider Ownership
AVDL Avadel Pharmaceuticals	5.20%
PCVX Vaxcyte	3.10%
PTCT PTC Therapeutics	5.50%
ZLAB Zai Lab	4.96%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AVDL Avadel Pharmaceuticals	70	96.74 million	91.71 million	Optionable
PCVX Vaxcyte	160	129.82 million	125.80 million	Optionable
PTCT PTC Therapeutics	1,410	79.44 million	75.07 million	Optionable
ZLAB Zai Lab	1,869	111.08 million	105.57 million	Optionable

AVDL, PCVX, PTCT, and ZLAB Headlines

Recent News About These Companies

US Bancorp DE Has $664,000 Stake in Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB)

August 12 at 3:36 AM | marketbeat.com

Zai Lab (NASDAQ:ZLAB) Issues Quarterly Earnings Results

August 10 at 9:22 PM | marketbeat.com

Here's What Analysts Are Forecasting For Zai Lab Limited (NASDAQ:ZLAB) After Its Second-Quarter Results

August 10 at 7:39 PM | finance.yahoo.com

Connor Clark & Lunn Investment Management Ltd. Buys 167,285 Shares of Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB)

August 10 at 6:37 AM | marketbeat.com

Mackenzie Financial Corp Purchases New Stake in Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB)

August 10 at 3:38 AM | marketbeat.com

XY Capital Ltd Invests $11.04 Million in Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB)

August 9 at 6:39 AM | marketbeat.com

Zai Lab (NASDAQ:ZLAB) Shares Gap Down - Should You Sell?

August 8, 2025 | marketbeat.com

Zai Lab Limited (ZLAB) Q2 2025 Earnings Call Transcript

August 7, 2025 | seekingalpha.com

Zai Lab reports Q2 EPS (4c), consensus (42c)

August 7, 2025 | msn.com

Zai Lab Misses Q2 Revenue Targets Despite EPS Beat; Shares Dip

August 7, 2025 | msn.com

Here's What Key Metrics Tell Us About Zai Lab Limited (ZLAB) Q2 Earnings

August 7, 2025 | zacks.com

This Cancer Treatment Stock Nears A Buy Point As Quarterly Results Loom

August 6, 2025 | investors.com

8,230 Shares in Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Purchased by Bank of New York Mellon Corp

August 5, 2025 | marketbeat.com

Zai Lab (ZLAB) Projected to Post Earnings on Thursday

August 5, 2025 | americanbankingnews.com

DCF Advisers LLC Buys 25,250 Shares of Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB)

August 4, 2025 | marketbeat.com

Privium Fund Management B.V. Trims Holdings in Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB)

August 3, 2025 | marketbeat.com

Alberta Investment Management Corp Sells 36,031 Shares of Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB)

August 3, 2025 | marketbeat.com

Short Interest in Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Grows By 7,956.7%

August 2, 2025 | marketbeat.com

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Sees Significant Increase in Short Interest

August 2, 2025 | americanbankingnews.com

TD Asset Management Inc Lowers Position in Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB)

July 31, 2025 | marketbeat.com

Zai Lab (ZLAB) Projected to Post Quarterly Earnings on Thursday

July 31, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

AVDL, PCVX, PTCT, and ZLAB Company Descriptions

Avadel Pharmaceuticals NASDAQ:AVDL

$13.40 +0.61 (+4.77%)

Closing price 04:00 PM Eastern

Extended Trading

$13.16 -0.24 (-1.75%)

As of 04:32 PM Eastern

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.

Vaxcyte NASDAQ:PCVX

$30.00 +0.33 (+1.11%)

Closing price 04:00 PM Eastern

Extended Trading

$30.74 +0.74 (+2.47%)

As of 05:18 PM Eastern

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

PTC Therapeutics NASDAQ:PTCT

$45.27 +1.97 (+4.55%)

Closing price 04:00 PM Eastern

Extended Trading

$45.28 +0.00 (+0.01%)

As of 05:29 PM Eastern

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.

Zai Lab NASDAQ:ZLAB

$34.31 -0.35 (-1.01%)

Closing price 04:00 PM Eastern

Extended Trading

$34.00 -0.31 (-0.90%)

As of 04:31 PM Eastern

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT. The company was incorporated in 2013 and is headquartered in Shanghai, China.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time